A handheld vagus nerve stimulation device used for the treatment of episodic cluster headaches has been approved by the Food and Drug Administration (FDA).

‘The Food and Drug Administration approved a device on Tuesday meant to treat cluster headaches — a rare form of headache that affects mostly men.’

The idea is to disrupt signals that run along the vagus nerve, a giant nerve that runs from the brain all the way to the colon. It's involved in many bodily responses.




The FDA’s release is based on analyses of data from 2 clinical trials, ACT1 and ACT2, which evaluated the safety and efficacy of gammaCore for the acute treatment of episodic cluster headache. Both trials were prospective, double-blind, placebo-controlled, randomized studies that evaluated the use of gammaCore versus a placebo.
The results from ACT1, which evaluated 81 patients, showed that 34.2% of patients experienced a reduction in pain after treatment compared with 10.6% of patients in the placebo group. Results from the ACT2 trial also demonstrated a significantly higher percentage of pain reduction in patients who used the product (47.4%) versus patients treated with a placebo (6.2%).
Both trials also demonstrated gammaCore’s safety and tolerability, with the majority of adverse events being mild and transient and occurring during the time of active treatment.
Prior to the FDA approval, there has not been any specific treatment for cluster headaches, but patients do take migraine drug sumatriptan, which is delivered through auto-injector, as well as inhaled oxygen. These methods are limited and often inconvenient.
Advertisement
Source-Medindia